Likes Subject
WOOHOOOOOO EW$ weedtrader420 05/04/22 3:11 PM
Weeeeeeeeeeeee weedtrader420 04/21/22 6:39 AM
WOOHOOOOOO weedtrader420 04/20/22 8:38 AM
EW$ weedtrader420 04/05/22 9:38 AM
Big move up EW WOOHOOOOOO weedtrader420 04/01/22 2:00 PM
3:1 Split for EW on June 1st. Adjust OldAIMGuy 06/02/20 8:06 AM
Have anyone see the earnings? Is that true Prominent Capital 04/25/20 8:45 AM
$EW great article whytestocks 11/12/19 6:25 PM
Ugh. Off 5% on the day. (along with OldAIMGuy 04/17/19 2:44 PM
EW up over 7% this AM with news OldAIMGuy 01/15/19 1:40 PM
A 7+% gain on share price this AM. OldAIMGuy 09/24/18 11:05 AM
Price/Share off 7% this AM. OldAIMGuy 07/27/18 9:54 AM
It's been a while since I updated my OldAIMGuy 03/12/18 11:48 AM
Thanks. It will be fun to watch unfold OldAIMGuy 05/16/17 8:29 AM
Nice reply and lets hope that Value Line Phaeton 05/15/17 4:44 PM
Hi P, Re: Long term with EW............. OldAIMGuy 05/15/17 7:40 AM
Can't wait to see where Edwards goes the Phaeton 05/14/17 1:25 PM
Surprised nobody is watching Edwards on this site. Phaeton 05/14/17 1:24 PM
5yr DCF imply Edwards Lifesciences $EW has 9% ValueInvestor15 01/31/17 4:58 PM
Hi J99, Re: Drop in price........... OldAIMGuy 10/27/16 12:19 PM
Still think this is oversold. Best in class jones99 10/26/16 4:09 AM
Saturday News.... Don 04/02/16 4:02 PM
Inst % Owned = 95% TREND1 03/06/16 5:51 PM
Float = 214.11M TREND1 03/06/16 5:50 PM
EPS = 2.30 TREND1 03/06/16 5:48 PM
EW DAY TREND1 03/06/16 5:48 PM
SEE MY POSTS AT TREND1 03/06/16 5:39 PM
Anybody following EW? Where are we heading Phaeton 05/23/14 6:16 PM
I'm out of this one for now. Glad robtewms 04/14/14 7:14 PM
fantastic move this morning.......... Belek 04/14/14 11:25 AM
not sure about that, EW has a 50/200ema Belek 03/10/14 1:06 PM
Thanks for sharing. In the past, outperform is robtewms 03/10/14 12:08 PM
Edwards Life Sciences u[graded this morning to Outperform Belek 03/10/14 10:37 AM
Thanks for sentiment. I like this company, but robtewms 03/06/14 4:42 PM
looks like EW on a upward trajectory for Belek 03/06/14 12:51 AM
Boom! Medtronic Corevalve early approval granted by the RealGenius 01/18/14 8:29 PM
This stock has been doing well in my robtewms 10/19/13 12:33 PM
Can you point out the interesting parts for robtewms 07/16/13 12:33 PM
Goldman-Sachs Global-Healthcare-Conference ECole 07/16/13 6:11 AM
I'm a new investor. What happened with knock-off? robtewms 07/09/13 7:20 PM
Look at ICU Medicals FloTrac knockoff. This could hurt Texstar 02/01/13 12:22 AM
TAVI: Mixed results for Edwards' Sapien valve in THESTCOKHUNTER 11/05/12 11:11 PM
Edwards Lifesciences (NYSE:EW) reported EPS of $0.58 in THESTCOKHUNTER 11/04/12 8:56 AM
there is interest,we just keep to ourselves, ihub THESTCOKHUNTER 10/24/12 10:37 PM
well, time to buy EW??????????? THESTCOKHUNTER 10/24/12 1:32 PM
EW, another guidance hit m177 10/09/12 10:00 AM
I can't understand why there is no interest dfeickeesq 06/26/12 7:17 AM
I believe that this is a likely split dfeickeesq 06/18/12 7:47 AM
I purchase this one on the low point, DrMG 02/21/12 6:20 PM
EW-stock analysis timvic 02/12/12 5:21 PM
Likes Subject

05/04/22 3:11 PM
04/21/22 6:39 AM
04/20/22 8:38 AM
04/05/22 9:38 AM
04/01/22 2:00 PM
06/02/20 8:06 AM
Prominent Capital
04/25/20 8:45 AM
04/17/19 2:44 PM
01/15/19 1:40 PM
09/24/18 11:05 AM
07/27/18 9:54 AM
03/12/18 11:48 AM
05/16/17 8:29 AM
05/15/17 4:44 PM
05/15/17 7:40 AM
05/14/17 1:25 PM
01/31/17 4:58 PM
10/27/16 12:19 PM
03/06/16 5:51 PM
03/06/16 5:50 PM
03/06/16 5:48 PM
03/06/16 5:48 PM
03/06/16 5:39 PM
04/14/14 7:14 PM
04/14/14 11:25 AM
10/19/13 12:33 PM
07/16/13 12:33 PM
11/05/12 11:11 PM
10/24/12 10:37 PM
10/24/12 1:32 PM
10/09/12 10:00 AM
06/26/12 7:17 AM
06/18/12 7:47 AM
02/12/12 5:21 PM

Edwards Life Sciences LLC (EW)

Posts (Today)
Posts (Total)

What Edwards Lifesciences Does
Edwards Lifesciences partners with physicians to innovate products designed to help patients live longer, healthier and more productive lives. We focus on medical technologies that address large and growing patient populations in which there are significant unmet clinical needs, such as structural heart disease and critical care monitoring.

Our technologies are categorized into our four business units - heart valve therapy, critical care, cardiac surgery systems and vascular - each with a rich history and unique patient focus.

Heart Valve Therapy
Since developing the first heart valve in 1958, we have continued to meaningfully advance heart valve therapy and, more than 50 years later, we remain the global leader in this field. Our offerings include tissue replacement heart valves and valve repair products, such as those marketed under the Carpentier-Edwards, Cosgrove-Edwards, Edwards Prima Plus, Edwards SAPIEN, Magna and PERIMOUNT brands. In addition, our new INTUITY aortic valve system is currently being studied in a European clinical trial.

We also lead the development of new investigative technologies designed for the non-surgical replacement of heart valves. We believe transcatheter valves hold great promise for patients considered high-risk for conventional valve replacement as this technology allows clinicians to deliver valves via a catheter, eliminating the need for traditional open-heart surgery. Our Edwards SAPIEN transcatheter heart valve has been commercially available in Europe since 2007 and is being studied in the U.S. PARTNER Trial, the world's first randomized clinical trial of a transcatheter heart valve. Our Edwards SAPIEN XT valve, the second commercially available transcatheter valve in the Edwards SAPIEN product portfolio, is currently being studied in Japan's first clinical trial of a transcatheter valve. We are the only company to commercialize both transfemoral and transapical transcatheter aortic valve systems.

Critical Care
We have been advancing critical care monitoring for more than 40 years, following the development of the Swan-Ganz line of hemodynamic monitoring devices - the gold-standard for measuring cardiovascular performance during surgical procedures and in post-surgical intensive care settings. Our FloTrac system is used to gather some of the same patient information as the Swan-Ganz catheter less invasively. Our PreSep oximetry catheter is used in an emergency room protocol called early goal-directed therapy, which has been clinically proven to significantly reduce death and healthcare expenses related to severe sepsis - the number one cause of death in the non-coronary intensive care unit.

In late 2010, we launched our VolumeView set and EV1000 clinical platform in Europe. When used with the EV1000 clinical platform, the VolumeView set measures a patient's volumetric hemodynamic parameters and provides more clarity for clinicians treating critically ill patients. In addition, our EV1000 clinical platform integrates many of our sensors and catheters into one intuitive system. With a touch-screen monitor that displays a patient's physiologic status, as well as color-coded clinical targets and alerts, this new clinical platform is designed to simplify decision-making in the hospital environment.

We are also developing our GlucoClear blood glucose monitoring system for the hospital environment. This new technology is designed to provide an enhanced level of trending insight to enable clinicians to effectively implement glycemic control with the intent of improving patient outcomes.

Cardiac Surgery Systems
Our cardiac surgery systems product line offers market-leading technologies that facilitate on-pump cardiac surgery procedures through smaller incisions. The Edwards Lifesciences minimally invasive valve surgery system is comprised of soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters, as well as reusable instruments for performing minimally invasive valvular procedures.

We also offer the Edwards Protection Cannulae product line, which is a global leader in the cardiovascular cannulae market. This product line features differentiated products used for venous drainage, aortic perfusion, venting, and cardioplegia delivery. Additionally, our EMBOL-X intra aortic filtration system is designed to capture emboli released at both application and release of the aortic cross clamp during on-pump cardiac surgery.

Our vascular product line includes the industry-standard Fogarty clot management catheters, which have evolved to meet specialists' clinical needs over the past 45 years. Additional vascular products include Fogarty clamp inserts and spring clips for the gentle occlusion of vessels during surgery, as well as other balloon-tipped catheters.

Heart Valve Therapies

Pericardial Heart Valves

Heart Valve Repair

Cardiac Cannula

Other Tissue Valves

Minimal Incision
Valve Surgery

General Investor Relations
Phone: (949) 250-2806
Fax:  (949) 250-2248

David K. Erickson
Vice President, Investor Relations
Phone: (949) 250-6826

Laci Smith
Sr. Analyst, Investor Relations
Phone: (949) 250-2816

Proxy and Stock Certificate Questions
Computershare Shareholder Services
P.O. Box 43010
Providence, RI 02940
(800) 446-2617

Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post